Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insmed

72.00
-4.2900-5.62%
Pre-market: 73.501.50+2.08%05:54 EDT
Volume:2.72M
Turnover:200.17M
Market Cap:13.03B
PE:-12.93
High:75.65
Open:75.35
Low:71.94
Close:76.29
Loading ...

Insmed Announces That FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients With Bronchiectasis

THOMSON REUTERS
·
24 Feb

Insmed Inc - FDA Reaffirms Priority Review for Brensocatib With Pdufa Date Aug 12, 2025

THOMSON REUTERS
·
24 Feb

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

PR Newswire
·
24 Feb

Insmed Price Target Announced at $90.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Feb

Insmed’s Earnings Call Highlights Record Growth and Strategic Moves

TIPRANKS
·
22 Feb

Truist Securities Adjusts Insmed Price Target to $108 From $105, Maintains Buy Rating

MT Newswires Live
·
21 Feb

Insmed Is Maintained at Buy by Stifel

Dow Jones
·
21 Feb

Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), InspireMD (NSPR)

TIPRANKS
·
21 Feb

Insmed Price Target Maintained With a $90.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Feb

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks
·
21 Feb

Insmed Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
21 Feb

Insmed (INSM) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
21 Feb

Insmed Inc (INSM) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

GuruFocus.com
·
21 Feb

Insmed’s Strong 2024 Growth and Promising Pipeline

TIPRANKS
·
21 Feb

Stock Track | Insmed Plummets 5.11% in Pre-Market as Wider Q4 Loss Disappoints

Stock Track
·
20 Feb

Insmed Inc - Reiterates 2025 Global Arikayce Revenue Guidance of $405 Mln-$425 Mln

THOMSON REUTERS
·
20 Feb

Insmed's Q4 Loss Widens, Revenue Rises

MT Newswires Live
·
20 Feb

Earnings Flash (INSM) Insmed Posts Q4 Net Revenue $104.4M, vs. FactSet Est of $102.1M

MT Newswires Live
·
20 Feb

Earnings Flash (INSM) Insmed Posts Q4 Net Loss $-1.32 a Share, vs. FactSet Est of $-1.17 Loss

MT Newswires Live
·
20 Feb

Insmed Continues To Anticipate Full-year 2025 Global Arikayce Revenues In The Range Of $405M-$425M, Representing Between 11% And 17% Year-over-year Growth Compared To 2024

Benzinga
·
20 Feb